Levetiracetam Hikma

Levetiracetam, the active ingredient in Levetiracetam Hikma, is an anticonvulsant presented as an intravenous solution for intravenous use. It is employed as adjunctive therapy for partial‑onset, generalized tonic‑clonic and myoclonic seizures in patients with epilepsy.

GNH USA supplies Levetiracetam Hikma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Levetiracetam is an antiepileptic medication that modulates neuronal excitability in seizure disorders.

- Partial‑onset seizures: reduces seizure frequency as adjunctive therapy. - Generalized tonic‑clonic seizures: provides additional seizure control when added to existing regimens. - Myoclonic seizures: improves management of myoclonic events as part of combination therapy.

Levetiracetam may be associated with a range of adverse reactions, varying in frequency and severity.

Common Side Effects: - Drowsiness: mild to moderate sedation. - Dizziness: sensation of light‑headedness. - Fatigue: reduced energy levels. - Headache: mild to moderate cranial pain.

Serious or Rare Side Effects: - Severe allergic reaction: rash, swelling, or anaphylaxis. - Mood changes: depression, suicidal thoughts, or aggression. - Hematologic abnormalities: thrombocytopenia or neutropenia.

When prescribing Levetiracetam, clinicians should consider several precautionary measures to ensure safe use.

- Renal impairment: adjust dose based on creatinine clearance. - Pregnancy: Category B; use only if benefit outweighs risk. - Psychiatric history: monitor for mood or behavioral changes. - Concomitant CNS depressants: assess additive sedation. - Pediatric use: follow age‑specific dosing recommendations. - Store at ambient temperature: keep below 25°C, protect from moisture and light, retain in original container.

Levetiracetam can interact with other medicines, affecting its concentration or therapeutic effect.

Major Interactions (Avoid): - Carbamazepine: may reduce levetiracetam plasma levels. - Phenobarbital: may decrease levetiracetam exposure.

Moderate Interactions (Monitor Closely): - Valproic acid: potential for increased adverse effects. - Other antiepileptic drugs (e.g., phenytoin, topiramate): may require dose adjustments. - Alcohol: may enhance central nervous system depression.